Leuven (BELGIUM) - April 29, 2011 - TiGenix (NYSE EURONEXT: TIG) is pleased to announce that ChondroCelect®, its cell based medicinal product for cartilage repair in the knee, will be available and reimbursed for hospital use in Belgium with effect from May 1st 2011. ChondroCelect is the first cell-based product that obtained a centralized European Marketing Authorization as an Advanced Therapy Medicinal Product (ATMP). Belgium is now the first country to provide national reimbursement for an ATMP.
